Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.
Latest website image capture
Clouds background image

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record and blocking access to the trial details.
    Difference
    18%
    Check dated 2026-09-23T00:06:37.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0 instead of v3.6.6, indicating an update to the site's interface version. This change relates to UI/versioning and does not alter the study details or content.
    Difference
    0.1%
    Check dated 2026-09-15T23:25:42.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, representing a backend/frontend platform update rather than content changes.
    Difference
    0.1%
    Check dated 2026-09-01T19:23:27.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The study's list of identifiers now includes '2016 ( U.S. NIH Grant/Contract )', adding NIH grant attribution to the record.
    Difference
    0.1%
    Check dated 2026-08-25T16:31:54.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A new revision label v3.6.5 was added to the page and the previous label v3.6.4 was removed, signaling a small platform build update.
    Difference
    0.0%
    Check dated 2026-08-11T08:07:42.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page revision metadata was updated from v3.6.3 to v3.6.4, signaling a minor update to the record's metadata; no changes to the study content are indicated.
    Difference
    0.0%
    Check dated 2026-07-28T05:17:49.000Z thumbnail image

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.